• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
XIE Yuan, WANG Hong, FENG Dong, HAO Haiping, WANG Guangji. Influence of curcumin on the pharmacokinetics of lovastatin in rats with fatty liver disease[J]. Journal of China Pharmaceutical University, 2013, 44(6): 543-547. DOI: 10.11665/j.issn.1000-5048.20130611
Citation: XIE Yuan, WANG Hong, FENG Dong, HAO Haiping, WANG Guangji. Influence of curcumin on the pharmacokinetics of lovastatin in rats with fatty liver disease[J]. Journal of China Pharmaceutical University, 2013, 44(6): 543-547. DOI: 10.11665/j.issn.1000-5048.20130611

Influence of curcumin on the pharmacokinetics of lovastatin in rats with fatty liver disease

More Information
  • Non-alcoholic fatty liver disease is always accompanied by hyperlipemia, hypercholesterolemia and hypertension requiring to multiple drugs for the treatment at the same time, which is quite possible to incur drug/drug interactions. This study aimed at investigating the pharmacokinetics of lovastatin, which is used for lowering cholesterol in those with hypercholesterolemia and hyperlipemia, in fatty liver disease rats treated with or without curcumin, a hepatoprotective agent. Serum biochemical analysis and histopathological study were undertaken to verify that a proper non-alcoholic fatty liver rat model was established for our pharmacokinetic study and the plasma concentration of lovastatin was determined in normal rats, high fat diet fed rats treated with or without curcumin. High fat diet causing rats fatty liver disease resulted in a nearly 1. 53-fold enhancement of plasma exposure of lovastatin, as well as 2. 54-fold of t1/2 of model group than the normal group. Curcumin treatment reversed the plasma exposure almost to the control level, as well as the level of cmax and t1/2. The main reason might be that hepatic CYP3A2 expression decreased in high fat diet fed rats while curcumin treatment largely enhanced CYP3A2 expression. This study suggested that long-term treatment with hepatoprotective agent curcumin would influence the pharmacokinetic behaviour of other drugs and the drug/drug interaction between hepatoprotective agents and co-prescribed drugs should be of concern during liver injury.
  • [1]
    Rivera-Espinoza Y,Muriel P.Pharmacological actions of curcumin in liver diseases or damage[J].Liver Int,2009,29(10):1 457-1 466.
    [2]
    Shao W,Yu Z,Chiang Y,et al.Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes[J].PLoS One,2012,7(1):e28784.
    [3]
    Kuo JJ,Chang HH,Tsai TH,et al.Curcumin ameliorates mitochondrial dysfunction associated with inhibition of gluconeogenesis in free fatty acid-mediated hepatic lipoapoptosis[J].Int J Mol Med,2012,30(3):643-649.
    [4]
    Kuo JJ,Chang HH,Tsai TH,et al.Positive effect of curcumin on inflammation and mitochondrial dysfunction in obese mice with liver steatosis[J].Int J Mol Med,2012,30(3):673-679.
    [5]
    Cheng PY,Wang M,Morgan ET.Rapid transcriptional suppression of rat cytochrome P450 genes by endotoxin treatment and its inhibition by curcumin[J].J Pharmacol Exp Ther,2003,307(3):1 205-1 212.
    [6]
    Chauvin B,Drouot S,Barrail-Tran A,et al.Drug-drug interactions between HMG-CoA reductase inhibitors(Statins)and antiviral protease inhibitors[J].Clin Pharmacokinet,2013,May 24.[Epub ahead of print].
    [7]
    Sun JG,Wang GJ,Xie L,et al.Rapid LC-MS determination and pharmacokinetic research of lovastatin in dog plasma[J].Chin J Pharm Anal(药物分析杂志),2006(1):44-47.
    [8]
    Park JS,Seo JH,Youn HS.Gut microbiota and clinical disease:obesity and nonalcoholic Fatty Liver disease[J].Pediatr Gastroenterol Hepatol Nutr,2013,16(1):22-27.
    [9]
    Salem NA,Assaf N,Ahmed HH.Pleiotropic effects of rimonabant and simvastatin on obesity associated multiple metabolic risk factors in rats[J].Eur Rev Med Pharmacol Sci,2012,16(6):797-807.
    [10]
    Schaalan MF.Effects of pioglitazone and/or simvastatin on circulating TNFα and adiponectin levels in insulin resistance[J].J Immunotoxicol,2012,9(2):201-209.
    [11]
    Patoine D,Levac X,Pilote S,et al.Decreased CYP3A expression and activity in guinea pig models of diet-induced metabolic syndrome:is fatty liver infiltration involved[J].Drug Metab Dispos,2013,41(5):952-957.
  • Related Articles

    [1]CHEN Feihong, ZHAO Deming, GOU Shaohua. Research progress on the antitumor effects of platinum-based chemo-immunotherapies[J]. Journal of China Pharmaceutical University, 2024, 55(1): 26-35. DOI: 10.11665/j.issn.1000-5048.2023120201
    [2]XU Yungen. Advances in drug development based on immunoregulation[J]. Journal of China Pharmaceutical University, 2024, 55(1): 1-4. DOI: 10.11665/j.issn.1000-5048.2024022601
    [3]YU Dongmei, GUO Wei, LEI Wen, GE Yaoyao, CHEN Yucong, GAO Xiangdong, YAO Wenbing. Advances of lncRNA in immune cells and autoimmune diseases[J]. Journal of China Pharmaceutical University, 2017, 48(3): 371-376. DOI: 10.11665/j.issn.1000-5048.20170319
    [4]LIANG Xiao-qing, SHI Chen-yang, WANG Ke, HE Xin, LIU Si-guo, HUANG Xiao-feng, LIU Yu. Anti-angiogenesis and anti-tumor activity of the fully human anti-VEGF165 monoclonal antibody obtained from the five-feature transgenic mice[J]. Journal of China Pharmaceutical University, 2012, 43(6): 560-566.
    [5]Tumor microenvironment:A novel target for antitumor activity of polysaccharides[J]. Journal of China Pharmaceutical University, 2010, 41(1): 1-10.
    [8]Effects of Mixed Nucleotide on Acute Hepatic Injury and Immunoregulation in Mice[J]. Journal of China Pharmaceutical University, 2001, (6): 44-47.
    [9]Immunomodulating Activity of Yang Zheng He Ji[J]. Journal of China Pharmaceutical University, 1995, (1): 37-40.
    [10]The Immunoregulative Effect of the Synthetic Artifact of Royel Jelly Acid[J]. Journal of China Pharmaceutical University, 1991, (2): 117-118.
  • Cited by

    Periodical cited type(3)

    1. 曾雪亮,钟文敏,李蓓. 异甘草酸镁联合疗法治疗慢性乙型肝炎的效果及安全性的meta分析. 中国当代医药. 2021(30): 13-17 .
    2. 高华,何海妮,刘莉娜. 异甘草酸镁注射液对耐多药结核鼠T淋巴细胞亚群及血清抗体的影响. 临床和实验医学杂志. 2020(22): 2382-2385 .
    3. 柏杰. 双环醇联合异甘草酸镁治疗失代偿期肝硬化疗效观察. 智慧健康. 2020(31): 115-116 .

    Other cited types(1)

Catalog

    Article views (1264) PDF downloads (1795) Cited by(4)

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return